Login Register Cart 0
Generic placeholder image

Current Cancer Therapy Reviews

Editor-in-Chief

ISSN (Print): 1573-3947
ISSN (Online): 1875-6301

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Research Article

Circulating MiR-1185¸ MiR-3183, and MiR-584 Levels in Plasma as Diagnostic Non-invasive Biomarkers for Early Detection of Breast Cancer

Author(s): Abolfazl Khalafi-Nezhad, Ahmad Abdollahi, Mahdi Barazesh*, Marzieh Amani, Setare Motazedi, Vahid Ebrahimi* and Ali Zarei

Volume 20, Issue 3, 2024

Published on: 27 September, 2023

Page: [307 - 319] Pages: 13

DOI: 10.2174/1573394719666230915103139

Price: $65

Abstract

Introduction: MicroRNAs (miRNAs) are non-coding RNA molecules with short sequences that function as main post-transcriptional gene regulators of different biological pathways via negative regulation of gene expression, thereby leading to either mRNA degradation or translational blockade. Dysregulated expression of these miRNAs has been related etiologically to many human diseases, including breast cancer. Various cellular processes of breast cancer progression, including cell proliferation, apoptosis, metastasis, recurrence and chemodrug resistance, are modulated by oncogenic miRNA (oncomiR).

Objective: The objective of this investigation was to study the expression level and potential diagnostic/ prognostic roles of circulating microRNAs (miR-3183, miR-1185, and miR-584) as novel breast cancer biomarkers.

Methods: The current study was conducted on 99 breast cancer (BC) female patients, aged between 20-63 years old, as the case group and 50 age-matched healthy females as control (HC). After microRNA extraction from the serum samples, real-time PCR was carried out for relative expression quantification of miR-1185, miR-3183a, and miR-584. The ROC curve analysis was performed to investigate the diagnostic value of miRNAs.

Results: It was demonstrated that miRNA-1185, miRNA-584, and miRNA-3183 were significantly up-regulated (p-values <0.0001) in female BC cases compared to the control group. Besides, based on the ROC analysis for BC versus HC, it was revealed that the AUC for miRNA-584 was 0.844 (95% confidence interval (CI) and could be proposed as a diagnostic biomarker for breast cancer screening and follow-up.

Conclusion: MiRNAs expression profiling using blood-based samples demonstrated their upregulation in the serum and plasma and revealed the concept that circulating miRNAs have high potential as novel noninvasive biomarkers for cancer diagnosis and screening.

Keywords: Breast cancer, oncomiR, diagnostic biomarker, circulating miRNAs, tumor recurrence, overall survival.

« Previous Next »
Graphical Abstract

[1]
Ghoncheh M, Pournamdar Z, Salehiniya H. Incidence and mortality and epidemiology of breast cancer in the world. Asian Pac J Cancer Prev 2016; 17(S3): 43-6.
[http://dx.doi.org/10.7314/APJCP.2016.17.S3.43] [PMID: 271652068]
[2]
Rivenbark AG, O’Connor SM, Coleman WB. Molecular and cellular heterogeneity in breast cancer: Challenges for personalized medicine. Am J Pathol 2013; 183(4): 1113-24.
[http://dx.doi.org/10.1016/j.ajpath.2013.08.002] [PMID: 23993780]
[3]
Miglietta F, Bottosso M, Griguolo G, Dieci MV, Guarneri V. Major advancements in metastatic breast cancer treatment: When expanding options means prolonging survival. ESMO Open 2022; 7(2): 100409.
[http://dx.doi.org/10.1016/j.esmoop.2022.100409] [PMID: 35227965]
[4]
Mayer EL, Krop IE. Advances in targeting SRC in the treatment of breast cancer and other solid malignancies. Clin Cancer Res 2010; 16(14): 3526-32.
[http://dx.doi.org/10.1158/1078-0432.CCR-09-1834] [PMID: 20634194]
[5]
Li J, Guan X, Fan Z, et al. Non-invasive biomarkers for early detection of breast cancer. Cancers 2020; 12(10): 2767.
[http://dx.doi.org/10.3390/cancers12102767] [PMID: 32992445]
[6]
Ling H, Fabbri M, Calin GA. MicroRNAs and other non-coding RNAs as targets for anticancer drug development. Nat Rev Drug Discov 2013; 12(11): 847-65.
[http://dx.doi.org/10.1038/nrd4140] [PMID: 24172333]
[7]
Yang Z, Liu Z. The emerging role of microRNAs in breast cancer. J of Oncol 2020; 2020: 9160905.
[http://dx.doi.org/10.1155/2020/9160905]
[8]
Liu X, Papukashvili D, Wang Z, et al. Potential utility of miRNAs for liquid biopsy in breast cancer. Front Oncol 2022; 12: 940314.
[http://dx.doi.org/10.3389/fonc.2022.940314] [PMID: 35992785]
[9]
Bertoli G, Cava C, Castiglioni I. MicroRNAs: New biomarkers for diagnosis, prognosis, therapy prediction and therapeutic tools for breast cancer. Theranostics 2015; 5(10): 1122-43.
[http://dx.doi.org/10.7150/thno.11543] [PMID: 26199650]
[10]
Cardinali B, Tasso R, Piccioli P, Ciferri MC, Quarto R, Del Mastro L. Circulating miRNAs in breast cancer diagnosis and prognosis. Cancers 2022; 14(9): 2317.
[http://dx.doi.org/10.3390/cancers14092317] [PMID: 35565446]
[11]
Yamamoto Y, Yoshioka Y, Minoura K, et al. An integrative genomic analysis revealed the relevance of microRNA and gene expression for drug-resistance in human breast cancer cells. Mol Cancer 2011; 10(1): 135.
[http://dx.doi.org/10.1186/1476-4598-10-135] [PMID: 22051041]
[12]
Adams BD, Kasinski AL, Slack FJ. Aberrant regulation and function of microRNAs in cancer. Curr Biol 2014; 24(16): R762-76.
[http://dx.doi.org/10.1016/j.cub.2014.06.043] [PMID: 25137592]
[13]
Syed SN, Brüne B. MicroRNAs as Emerging Regulators of Signaling in the Tumor Microenvironment. Cancers (Basel) 2020; Apr 8; 12(4): 911.
[http://dx.doi.org/10.3390/cancers12040911] [PMID: 32276464] [PMCID: PMC7225969]
[14]
Rezaei Z, Sadri F. MicroRNAs involved in inflammatory breast cancer: Oncogene and tumor suppressors with possible targets. DNA Cell Biol 2021; 40(3): 499-512.
[http://dx.doi.org/10.1089/dna.2020.6320] [PMID: 33493414]
[15]
Wang W, Luo Y. MicroRNAs in breast cancer: Oncogene and tumor suppressors with clinical potential. J Zhejiang Univ Sci B 2015; 16(1): 18-31.
[http://dx.doi.org/10.1631/jzus.B1400184] [PMID: 25559952]
[16]
Li Q, Li Z, Wei S, et al. Overexpression of miR-584-5p inhibits proliferation and induces apoptosis by targeting WW domain-containing E3 ubiquitin protein ligase 1 in gastric cancer. J Exp Clin Cancer Res 2017; 36(1): 59.
[http://dx.doi.org/10.1186/s13046-017-0532-2] [PMID: 28431583]
[17]
Alqurashi N, Hashimi S, Alowaidi F, Ivanovski S, Farag A, Wei M. miR 496, miR 1185, miR 654, miR 3183 and miR 495 are downregulated in colorectal cancer cells and have putative roles in the mTOR pathway. Oncol Lett 2019; 18(2): 1657-68.
[http://dx.doi.org/10.3892/ol.2019.10508] [PMID: 31423233]
[18]
Giussani M, Ciniselli CM, De Cecco L, et al. Circulating miRNAs as novel non-invasive biomarkers to aid the early diagnosis of suspicious breast lesions for which biopsy is recommended. Cancers 2021; 13(16): 4028.
[http://dx.doi.org/10.3390/cancers13164028] [PMID: 34439180]
[19]
El-Toukhy SE, El-Daly SM, Kamel MM, Nabih HK. The diagnostic significance of circulating miRNAs and metabolite profiling in early prediction of breast cancer in Egyptian women. J Cancer Res Clin Oncol 2022.
[PMID: 36459290]
[20]
Cuk K, Zucknick M, Heil J, et al. Circulating microRNAs in plasma as early detection markers for breast cancer. Int J Cancer 2013; 132(7): 1602-12.
[http://dx.doi.org/10.1002/ijc.27799] [PMID: 22927033]
[21]
Bansal C, Singh US, Misra S, Sharma KL, Tiwari V, Srivastava AN. Comparative evaluation of the modified Scarff-Bloom-Richardson grading system on breast carcinoma aspirates and histopathology. Cytojournal 2012; 9: 4.
[http://dx.doi.org/10.4103/1742-6413.92550] [PMID: 22363393]
[22]
Cihan M, Andrade-Navarro MA. Detection of features predictive of microRNA targets by integration of network data. PLoS One 2022; 17(6): e0269731.
[http://dx.doi.org/10.1371/journal.pone.0269731] [PMID: 35679295]
[23]
Huang H-Y, Lin Y-C-D, Li J, et al. miRTarBase 2020: Updates to the experimentally validated microRNA-target interaction database. Nucleic Acids Res 2020; 48(D1): D148-54.
[PMID: 31647101]
[24]
Licursi V, Conte F, Fiscon G, Paci P. MIENTURNET: An interactive web tool for microRNA-target enrichment and network-based analysis. BMC Bioinformatics 2019; 20(1): 545.
[http://dx.doi.org/10.1186/s12859-019-3105-x] [PMID: 31684860]
[25]
Heywang-Köbrunner SH, Hacker A, Sedlacek S. Advantages and disadvantages of mammography screening. Breast Care 2011; 6(3): 2.
[http://dx.doi.org/10.1159/000329005] [PMID: 21779225]
[26]
Luo C, Wang L, Zhang Y, et al. Advances in breast cancer screening modalities and status of global screening programs. Chronic Dis Transl Med 2022; 8(2): 112-23.
[http://dx.doi.org/10.1002/cdt3.21] [PMID: 35774423]
[27]
Campuzano S, Pedrero M,. Pingarrón J. Non-invasive breast cancer diagnosis through electrochemical biosensing at different molecular levels. Sensors 2017; 17(9): 1993.
[http://dx.doi.org/10.3390/s17091993] [PMID: 28858236]
[28]
Menon A, Abd-Aziz N, Khalid K, Poh CL, Naidu R. miRNA: A Promising therapeutic target in cancer. Int J Mol Sci 2022; 23(19): 11502.
[http://dx.doi.org/10.3390/ijms231911502] [PMID: 36232799]
[29]
Otmani K, Lewalle P. Tumor suppressor mirna in cancer cells and the tumor microenvironment: Mechanism of deregulation and clinical implications. Front Oncol 2021; 11: 708765.
[http://dx.doi.org/10.3389/fonc.2021.708765] [PMID: 34722255]
[30]
Palmero EI, Campos SGP, Campos M, et al. Mechanisms and role of microRNA deregulation in cancer onset and progression. Genet Mol Biol 2011; 34(3): 363-70.
[http://dx.doi.org/10.1590/S1415-47572011000300001] [PMID: 21931505]
[31]
Sharma PC, Gupta A. MicroRNAs: Potential biomarkers for diagnosis and prognosis of different cancers. Transl Cancer Res 2020; 9(9): 5798-818.
[http://dx.doi.org/10.21037/tcr-20-1294] [PMID: 35117940]
[32]
Wang H, Peng R, Wang J, Qin Z, Xue L. Circulating microRNAs as potential cancer biomarkers: The advantage and disadvantage. Clin Epigenetics 2018; 10(1): 59.
[http://dx.doi.org/10.1186/s13148-018-0492-1] [PMID: 29713393]
[33]
Mitchell PS, Parkin RK, Kroh EM, et al. Circulating microRNAs as stable blood-based markers for cancer detection. Proc Natl Acad Sci USA 2008; 105(30): 10513-8.
[http://dx.doi.org/10.1073/pnas.0804549105] [PMID: 18663219]
[34]
Abramovic I, Vrhovec B, Skara L, et al. MiR-182-5p and miR-375-3p have higher performance than psa in discriminating prostate cancer from benign prostate hyperplasia. Cancers 2021; 13(9): 2068.
[http://dx.doi.org/10.3390/cancers13092068] [PMID: 33922968]
[35]
Powrózek T, Krawczyk P, Kowalski DM, et al. Application of plasma circulating microRNA-448, 506, 4316, and 4478 analysis for non-invasive diagnosis of lung cancer. Tumour Biol 2016; 37(2): 2049-55.
[http://dx.doi.org/10.1007/s13277-015-3971-4] [PMID: 26341493]
[36]
Fang Z, Tang J, Bai Y, et al. Plasma levels of microRNA-24, microRNA-320a, and microRNA-423-5p are potential biomarkers for colorectal carcinoma. J Exp Clin Cancer Res 2015; 34(1): 86.
[http://dx.doi.org/10.1186/s13046-015-0198-6] [PMID: 26297223]
[37]
Shimomura A, Shiino S, Kawauchi J, et al. Novel combination of serum microRNA for detecting breast cancer in the early stage. Cancer Sci 2016; 107(3): 326-34.
[http://dx.doi.org/10.1111/cas.12880] [PMID: 26749252]
[38]
Hannafon BN, Trigoso YD, Calloway CL, et al. Plasma exosome microRNAs are indicative of breast cancer. Breast Cancer Res 2016; 18(1): 90.
[http://dx.doi.org/10.1186/s13058-016-0753-x] [PMID: 27608715]
[39]
Gasparello J, Papi C, Zurlo M, et al. MicroRNAs miR-584-5p and miR-425-3p Are up-regulated in plasma of colorectal cancer (CRC) Patients: Targeting with inhibitor peptide nucleic acids is associated with induction of apoptosis in colon cancer cell lines. Cancers 2022; 15(1): 128.
[http://dx.doi.org/10.3390/cancers15010128] [PMID: 36612125]
[40]
Ebrahimi Ghahnavieh L, Tabatabaeian H, Ebrahimi Ghahnavieh Z, et al. Fluctuating expression of miR-584 in primary and high-grade gastric cancer. BMC Cancer 2020; 20(1): 621.
[http://dx.doi.org/10.1186/s12885-020-07116-5] [PMID: 32615958]
[41]
Garcia-Moreno A, Carmona-Saez P. Computational methods and software tools for functional analysis of miRNA data. Biomolecules 2020; 10(9): 1252.
[http://dx.doi.org/10.3390/biom10091252] [PMID: 32872205]
[42]
Nagaraj NS, Datta PK. Targeting the transforming growth factor-β signaling pathway in human cancer. Expert Opin Investig Drugs 2010; 19(1): 77-91.
[http://dx.doi.org/10.1517/13543780903382609] [PMID: 20001556]
[43]
Zhang M, Zhang YY, Chen Y, Wang J, Wang Q, Lu H. TGF-β signaling and resistance to cancer therapy. Front Cell Dev Biol 2021; 9: 786728.
[http://dx.doi.org/10.3389/fcell.2021.786728] [PMID: 34917620]
[44]
Baba AB, Rah B, Bhat GR, et al. Transforming growth factor-beta (TGF-β) signaling in cancer-a betrayal within. Front Pharmacol 2022; 13: 791272.
[http://dx.doi.org/10.3389/fphar.2022.791272] [PMID: 35295334]
[45]
Kim BG, Malek E, Choi SH, Ignatz-Hoover JJ, Driscoll JJ. Novel therapies emerging in oncology to target the TGF-β pathway. J Hematol Oncol 2021; 14(1): 55.
[http://dx.doi.org/10.1186/s13045-021-01053-x] [PMID: 33823905]
[46]
Principe DR, Doll JA, Bauer J, et al. TGF-β: Duality of function between tumor prevention and carcinogenesis. J Natl Cancer Inst 2014; 106(2): djt369.
[http://dx.doi.org/10.1093/jnci/djt369] [PMID: 24511106]
[47]
Ivanović V, Demajo M, Krtolica K, et al. Elevated plasma TGF-β1 levels correlate with decreased survival of metastatic breast cancer patients. Clin Chim Acta 2006; 371(1-2): 191-3.
[http://dx.doi.org/10.1016/j.cca.2006.02.027] [PMID: 16650397]
[48]
Liu Z, Zhang Y, Zhang L, et al. Duality of interactions between TGF-β and TNF-α during tumor formation. Front Immunol 2022; 12: 810286.
[http://dx.doi.org/10.3389/fimmu.2021.810286] [PMID: 35069596]
[49]
Sheen YY, Kim MJ, Park SA, Park SY, Nam JS. Targeting the transforming growth factor-β signaling in cancer therapy. Biomol Ther 2013; 21(5): 323-31.
[http://dx.doi.org/10.4062/biomolther.2013.072] [PMID: 24244818]
[50]
Suzuki H. MicroRNA control of TGF-β signaling. Int J Mol Sci 2018; 19(7): 1901.
[http://dx.doi.org/10.3390/ijms19071901] [PMID: 29958433]
[51]
Gregory PA, Bert AG, Paterson EL, et al. The miR-200 family and miR-205 regulate epithelial to mesenchymal transition by targeting ZEB1 and SIP1. Nat Cell Biol 2008; 10(5): 593-601.
[http://dx.doi.org/10.1038/ncb1722] [PMID: 18376396]
[52]
Keklikoglou I, Koerner C, Schmidt C, et al. MicroRNA-520/373 family functions as a tumor suppressor in estrogen receptor negative breast cancer by targeting NF-κB and TGF-β signaling pathways. Oncogene 2012; 31(37): 4150-63.
[http://dx.doi.org/10.1038/onc.2011.571] [PMID: 22158050]
[53]
Fils-Aimé N, Dai M, Guo J, et al. MicroRNA-584 and the protein phosphatase and actin regulator 1 (PHACTR1), a new signaling route through which transforming growth factor-β Mediates the migration and actin dynamics of breast cancer cells. J Biol Chem 2013; 288(17): 11807-23.
[http://dx.doi.org/10.1074/jbc.M112.430934] [PMID: 23479725]
[54]
Wang P, Liu X, Ding L, Zhang X, Ma Z. mTOR signalingrelated MicroRNAs and Cancer involvement. J Cancer 2018; 9(4): 667-73.
[http://dx.doi.org/10.7150/jca.22119] [PMID: 29556324]
[55]
Zhang Y, Huang B, Wang HY, Chang A, Zheng XFS. Emerging role of microRNAs in mTOR signaling. Cell Mol Life Sci 2017; 74(14): 2613-25.
[http://dx.doi.org/10.1007/s00018-017-2485-1] [PMID: 28238105]
[56]
Zou Z, Tao T, Li H, Zhu X. mTOR signaling pathway and mTOR inhibitors in cancer: Progress and challenges. Cell Biosci 2020; 10(1): 31.
[http://dx.doi.org/10.1186/s13578-020-00396-1] [PMID: 32175074]
[57]
Hare SH, Harvey AJ. mTOR function and therapeutic targeting in breast cancer. Am J Cancer Res 2017; 7(3): 383-404.
[PMID: 28400999]
[58]
Tian T, Li X, Zhang J. mTOR signaling in cancer and mTOR inhibitors in solid tumor targeting therapy. Int J Mol Sci 2019; 20(3): 755.
[http://dx.doi.org/10.3390/ijms20030755] [PMID: 30754640]
[59]
Mazumdar A, Tahaney WM, Hill JL, et al. Targeting the mTOR Pathway for the prevention of er-negative breast cancer. Cancer Prev Res 2022; 15(12): 791-802.
[http://dx.doi.org/10.1158/1940-6207.CAPR-22-0106] [PMID: 35981902]
[60]
Akbarzadeh M, Mihanfar A, Akbarzadeh S, Yousefi B, Majidinia M. Crosstalk between miRNA and PI3K/AKT/mTOR signaling pathway in cancer. Life Sci 2021; 285: 119984.
[http://dx.doi.org/10.1016/j.lfs.2021.119984] [PMID: 34592229]
[61]
Urbanek-Trzeciak MO, Galka-Marciniak P, Nawrocka PM, et al. Pan-cancer analysis of somatic mutations in miRNA genes. EBioMedicine 2020; 61: 103051.
[http://dx.doi.org/10.1016/j.ebiom.2020.103051] [PMID: 33038763]
[62]
Machowska M, Galka-Marciniak P, Kozlowski P. Consequences of genetic variants in miRNA genes. Comput Struct Biotechnol J 2022; 20: 6443-57.
[http://dx.doi.org/10.1016/j.csbj.2022.11.036] [PMID: 36467588]
[63]
Galka-Marciniak P, Urbanek-Trzeciak MO, Nawrocka PM, et al. Somatic mutations in miRNA genes in lung cancer—potential functional consequences of non-coding sequence variants. Cancers 2019; 11(6): 793.
[http://dx.doi.org/10.3390/cancers11060793] [PMID: 31181801]
[64]
Shen J, Ambrosone CB, Zhao H. Novel genetic variants in microRNA genes and familial breast cancer. Int J Cancer 2009; 124(5): 1178-82.
[http://dx.doi.org/10.1002/ijc.24008] [PMID: 19048628]
[65]
Rawlings-Goss RA, Campbell MC, Tishkoff SA. Global population-specific variation in miRNA associated with cancer risk and clinical biomarkers. BMC Med Genomics 2014; 7(1): 53.
[http://dx.doi.org/10.1186/1755-8794-7-53] [PMID: 25169894]

Rights & Permissions Print Cite
Article Metrics
9
1
© 2024 Bentham Science Publishers | Privacy Policy